Fallopian Tube Diseases: Clinical Trials

384 trials for Fallopian Tube Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

189 completed, 58 terminated, 45 recruiting, 39 active not recruiting. 384 Phase 2, 80 Phase 1, 11 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2384Completed 189, Terminated 58, Recruiting 45, Active not recruiting 39, Unknown 28, Withdrawn 15, Not yet recruiting 9, Suspended 1
Phase 180Completed 28, Terminated 19, Recruiting 13, Active not recruiting 10, Withdrawn 5, Unknown 3, Not yet recruiting 1, Suspended 1
Phase 311Completed 4, Active not recruiting 2, Recruiting 2, Not yet recruiting 1, Terminated 1, Unknown 1

Follow Fallopian Tube Diseases: new trials by email Literature Review of Fallopian Tube Diseases trials Research Report on Fallopian Tube Diseases

Trials (filtered) newest first · largest first

All 384 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Losartan and Paclitaxel in Platinum Resistant Ovarian Cancer
losartan, Paclitaxel - Platinum Resistant Ovarian Cancer
Phase 2Not yet recruitingMassachusetts General Hospital272027-02-012026-09-22
PDS Versus NACT-IDS in AI-Selected Advanced Epithelial Ovarian Cancer
Upfront cytoreductive surgery, Interval debulking surgery, Platinum-based chemotherapy - Epithelial Ovarian Cancer, Fallopian Tube Cancers
Phase 2 / Phase 3Not yet recruitingShanghai Gynecologic Oncology Group5342026-12-312026-11-12
Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer
Trastuzumab Rezetecan (SHR-A1811), Bevacizumab, Platinum-based chemotherapy - Ovarian Cancer, Fallopian Tube Cancers
Phase 2Not yet recruitingPeking University Cancer Hospital & Institute532026-10-222026-10-01
IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence
pUMVC3-hIGFBP-2 Multi-epitope Plasmid DNA Vaccine, Carboplatin, Computed Tomography - Fallopian Tube Carcinoma, Ovarian Carcinoma
Phase 2RecruitingUniversity of Washington262026-09-162026-11-02
Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and Atorvastatin
Standard of Care + atorvastatin, Standard of Care (SOC) - Ovarian Cancer, Fallopian Tube Cancers
Phase 2Not yet recruitingUniversity of Colorado, Denver402026-09-012026-09-11
Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer
Aitua Combination Antibody, Albumin-Bound Paclitaxel /nab-Paclitaxel, Carboplatin (AUC 5) - High-grade Serous Ovarian Cancer (HGSOC), Fallopian Tube Cancers
Phase 2RecruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences822026-07-232026-11-04
Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer
Liposomal Irinotecan - Platinum-resistant Recurrent Ovarian Cancer, Fallopian Tube Cancers
Phase 2Not yet recruitingTianjin Medical University Cancer Institute and Hospital302026-05-302026-05-18
Benmelstobart in Combination With Anlotinib and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial OvariaN, Fallopian Tube, or Primary Peritoneal Cancer
Benmelstobart in combination with Anlotinib and oral metronomic Cyclophosphamide - Ovarian Cancer, Fallopian Tube Cancers
Phase 2Not yet recruitingSecond Affiliated Hospital, Zhejiang University, School of Medicine402026-03-302026-03-24
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2
Dual-target CAR-NK cell product, Cyclophosphamide, supportive - Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma
Phase 1 / Phase 2RecruitingBeijing Biotech362026-03-022026-06-01
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)
Dual-target CAR-NK cell product, Lymphodepleting chemotherapy, Standard supportive care - Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma
Phase 1 / Phase 2RecruitingBeijing Biotech362026-02-042026-03-18
Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors
Romiplostim N01, All-trans retinoic acid - Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia
Phase 2RecruitingPeking University People's Hospital2202025-12-222026-05-14
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Cancer Therapeutic Procedure, Questionnaire Administration - Amyloidosis, Basal Cell Carcinoma
Phase 2RecruitingMayo Clinic272025-12-182026-09-30
CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer
TORL-1-23 and paclitaxel, TORL-1-23 and carboplatin, TORL-1-23, paclitaxel, and carboplatin - FIGO Stage III and IV Ovarian Cancer, Fallopian Tube Cancers
Phase 1 / Phase 2RecruitingTORL Biotherapeutics, LLC602025-12-102026-07-13
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Carboplatin, Mirvetuximab Soravtansine, Bevacizumab - Epithelial Ovarian Cancer, Fallopian Tube Cancer
Phase 2RecruitingAbbVie1402025-11-212026-10-20
Phase II Clinical Study of Utidelone Capsule (UTD2) in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Utidelone capsule 75mg/m2/d QD, Utidelone capsule 40mg/m2/d BID, Utidelone capsule 50mg/m2/d BID - Ovarian Cancer, Fallopian Tube Cancer
Phase 2Not yet recruitingBeijing Biostar Pharmaceuticals Co., Ltd.722025-09-012025-06-30
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
IMGN151, Carboplatin, Bevacizumab - Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer
Phase 2RecruitingAbbVie3772025-07-302026-10-01
PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer
PARP inhibitor + Bevacizumab, PARP inhibitor - Ovarian Cancer, Fallopian Tube Cancers
Phase 2 / Phase 3RecruitingN.N. Alexandrov National Cancer Centre1202025-07-012026-03-16
Surgery for Relapsed Ovarian Cancer in Precision
surgery/chemotherapy, Iparomlimab/Tuvonralimab - Epithelial Ovarian Cancer, Fallopian Tube Cancer
Phase 1 / Phase 2Not yet recruitingShanghai Gynecologic Oncology Group332025-07-012025-06-27
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
Mirvetuximab Soravtansine - Advanced High-Grade Epithelial Ovarian Cancer, Primary Peritoneal Cancer
Phase 2RecruitingAbbVie1102025-05-282026-05-26
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Ubamatamab, Bevacizumab, Cemiplimab - Ovarian Cancer, Fallopian Tube Cancer
Phase 2RecruitingRegeneron Pharmaceuticals3972025-05-282026-11-06

Showing 20 of 384. Sign in to see all of them.

Narrower conditions

Fallopian Tube Neoplasms (382)  ·  Ovarian Neoplasms (314)  ·  Carcinoma, Ovarian Epithelial (141)  ·  Endometrial Neoplasms (30)  ·  Neoplasms (23)  ·  Recurrence (21)  ·  Peritoneal Neoplasms (20)  ·  Uterine Cervical Neoplasms (19)  ·  Breast Neoplasms (17)  ·  Brenner Tumor (13)  ·  Triple Negative Breast Neoplasms (11)  ·  Carcinoma (10)  ·  Neoplasm Metastasis (10)  ·  Sarcoma (8)  ·  Ovarian Diseases (7)

Broader conditions

Female Urogenital Diseases (384)  ·  Female Urogenital Diseases and Pregnancy Complications (384)  ·  Genital Diseases (384)  ·  Urogenital Diseases (384)  ·  Adnexal Diseases (383)  ·  Genital Diseases, Female (381)  ·  Urogenital Neoplasms (380)  ·  Neoplasms by Site (378)  ·  Genital Neoplasms, Female (377)  ·  Gonadal Disorders (365)  ·  Endocrine Gland Neoplasms (364)  ·  Endocrine System Diseases (363)  ·  Neoplasms (360)  ·  Ovarian Diseases (359)

Interventions

Carboplatin (81)  ·  Paclitaxel (75)  ·  Bevacizumab (51)  ·  Gemcitabine (24)  ·  Taxes (23)  ·  pembrolizumab (23)  ·  liposomal doxorubicin (19)  ·  Topotecan (18)  ·  Disulfides (16)  ·  Immunoglobulin G (16)  ·  olaparib (15)  ·  Cisplatin (13)  ·  Cyclophosphamide (13)  ·  niraparib (12)  ·  Specimen Handling (11)

Sponsors

National Cancer Institute (NCI) (46)  ·  M.D. Anderson Cancer Center (15)  ·  Gynecologic Oncology Group (14)  ·  Dana-Farber Cancer Institute (11)  ·  Memorial Sloan Kettering Cancer Center (10)  ·  Roswell Park Cancer Institute (9)  ·  Mayo Clinic (8)  ·  AGO Study Group (6)  ·  Shanghai Gynecologic Oncology Group (6)  ·  University Health Network, Toronto (6)  ·  AbbVie (5)  ·  Eli Lilly and Company (5)  ·  Masonic Cancer Center, University of Minnesota (5)  ·  Massachusetts General Hospital (5)  ·  University College, London (5)

Countries

United States (274)  ·  Canada (41)  ·  United Kingdom (29)  ·  Spain (27)  ·  China (25)  ·  Germany (23)  ·  Belgium (21)  ·  Italy (19)  ·  Australia (18)  ·  South Korea (18)  ·  France (17)  ·  Japan (10)  ·  Netherlands (9)  ·  Austria (7)  ·  Singapore (6)

Top investigators

Emese Zsiros (5)  ·  Ursula Matulonis, MD (5)  ·  Amit Oza (4)  ·  Amy D. Tiersten, MD (4)  ·  Paul Sabbatini, MD (4)  ·  Robert Coleman (3)  ·  Amir A Jazaeri (2)  ·  Amir Jazaeri, MD (2)  ·  Amit Oza, M.D. (2)  ·  Andreas du Bois, MD, PhD (2)  ·  Bradley J Monk (2)  ·  Bradley J. Monk, MD (2)

Results publications

PMID 37185961, PMID 23810467, PMID 25218906, PMID 31685558, PMID 35170751, PMID 35397664, PMID 10623700, PMID 10628376, PMID 10793106, PMID 11309294, PMID 11331762, PMID 11459964, PMID 11533692, PMID 12205100, PMID 12217790, PMID 12241653, PMID 12460789, PMID 14615449, PMID 14645425, PMID 14701743, PMID 15327776, PMID 15367671, PMID 15661234, PMID 15665856, PMID 15699482, PMID 1581961, PMID 15829966, PMID 15829967, PMID 15905196, PMID 16014111, PMID 16239238, PMID 16357170, PMID 16394300, PMID 16912188, PMID 16946210, PMID 17161453, PMID 17330838, PMID 17714938, PMID 17910981, PMID 17918264, PMID 18024865, PMID 18268546, PMID 18538834, PMID 18829088, PMID 18955455, PMID 19049966, PMID 19058838, PMID 19138791, PMID 19181369, PMID 19238149

NIH funding

U10CA180868 (19), U10CA027469 (17), N01CM62203 (6), N01CM62201 (5), N01CM62209 (5), N01CM00071 (4), P30CA016056 (4), U10CA032102 (4), 2023 (3), N01CM00032 (3), N01CM00038 (3), N01CM62204 (3), P30CA015083 (3), P30CA015704 (3), P50CA136393 (3)